$ 31,935$ 25,216$ 6,71927%Assays and related products
43,27533,25210,02330%Operating income (loss)Technology and strategic partnerships
8,6564,2964,360101%Assays and related products
(362)(548)18634%Total Operating income
8,2943,7484,546121%FINANCIAL OUTLOOK AND GUIDANCE The Company reaffirms its 2011 annual revenue guidance of between $163 and $170 million.
CONFERENCE CALL Management will host a conference call to discuss the operating highlights and financial results for the first quarter ended March 31, 2011, on Monday, May 9, 2011, at 4:00 p.m. Central time/ 5:00 p.m. Eastern time. The conference call will be webcast live and will be accompanied by a slide presentation, both of which may be accessed at Luminex Corporation's website at http://www.luminexcorp.com. Simply log on to the web at the address above, go to the Company section and access the Investor Relations link. Please go to the website at least 15 minutes prior to the call to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the call and slides will be archived for six months on the website using the 'replay' link.
Luminex develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry. The Company's xMAP system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical researc
|SOURCE Luminex Corporation|
Copyright©2010 PR Newswire.
All rights reserved